Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study
CONCLUSION: Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis.PMID:35688451 | DOI:10.1055/s-0042-1743473
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Anne Gulbech Ording Flemming Skj øth S øren Due Andersen Torben Bjerregaard Larsen Source Type: research

Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research

Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
CONCLUSIONS: Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke, and a lower risk of major bleeding compared with rivaroxaban.PMID:35292949 | DOI:10.1055/a-1798-2116
Source: Thrombosis and Haemostasis - March 16, 2022 Category: Hematology Authors: Krishna Roy Chowdhury Jonathan Michaud Oriana Hoi Yun Yu Hui Yin Laurent Azoulay Christel Renoux Source Type: research

Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A  Danish population-based cohort study
CONCLUSION: In patients with AFF, liver cirrhosis was associated with an elevated risk of ischemic stroke, venous thromboembolism, and all evaluated bleeding complications.PMID:35229067 | PMC:PMC8867136 | DOI:10.1002/rth2.12668
Source: Thrombosis and Haemostasis - March 1, 2022 Category: Hematology Authors: Emil B Riahi Kasper Adelborg Lars Pedersen S øren R Kristensen Anette T Hansen Henrik T S ørensen Source Type: research

State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism
Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1778-1083. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and co-morbidities pr...
Source: Thrombosis and Haemostasis - February 21, 2022 Category: Hematology Authors: Mark Goldin Ioannis Koulas Jeffrey I Weitz Alex Spyropoulos Source Type: research

Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention
CONCLUSIONS: Monitoring of DOAC plasma levels could help to identify patients with increased risk for stroke recurrence and should be considered for certain subgroups, including patients with high GFR.PMID:35171533 | DOI:10.1111/jth.15677
Source: Thrombosis and Haemostasis - February 16, 2022 Category: Hematology Authors: Gabriela Siedler Kosmas Macha Svenja Stoll Johannes Plechschmidt Ruihao Wang Stefan T Gerner Erwin Strasser Stefan Schwab Bernd Kallm ünzer Source Type: research

Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification?
Thromb Haemost. 2022 Jan 19. doi: 10.1055/a-1745-2083. Online ahead of print.ABSTRACTPatients with heart failure (HF) in sinus rhythm (SR) experience an increased incidence of thromboembolic events including stroke. Among patients with HF, high-quality evidence supports the use of oral anticoagulation when atrial fibrillation (AF) is present, but the benefit of anticoagulation in SR in absence of other known indications for anticoagulation is unclear. In four randomized controlled trials (RCTs), warfarin did not improve a composite of clinical outcomes compared with aspirin or placebo in patients with HF with reduced eject...
Source: Thrombosis and Haemostasis - January 19, 2022 Category: Hematology Authors: Angelica Rivas Mandy N Lauw Renate Bonin-Schnabel Mark Crowther Harriette Van Spall Source Type: research

The PAR4 platelet thrombin receptor variant rs773902 does not impact the incidence of thrombotic or bleeding events in a healthy older population
CONCLUSIONS: This post-hoc analysis of a prospective cohort study suggests that, despite sensitizing platelet activation, the rs773902 PAR4 variant is not associated with thrombotic cardiovascular or bleeding events in a healthy older population.PMID:34852379 | DOI:10.1055/a-1711-1395
Source: Thrombosis and Haemostasis - December 1, 2021 Category: Hematology Authors: Maria V Selvadurai Moeen Riaz Sophia Xie Andrew Tonkin John J McNeil Paul Lacaze Justin Hamilton Source Type: research

XJ-8, a natural compound isolated from Sanguis draxonis, inhibits platelet function and thrombosis by targeting MAP3K3
CONCLUSION: XJ-8 can inhibit platelet function and thrombosis by targeting MAP3K3, and has potential to be developed into a novel therapeutic agent for the treatment of thrombotic diseases.PMID:34780114 | DOI:10.1111/jth.15593
Source: Thrombosis and Haemostasis - November 15, 2021 Category: Hematology Authors: Zhixiang Zhu Lili Wang Ran Guo Daoran Pang Wenxuan Wang Yan Wu Ning Wei Jun Li Pengfei Tu Source Type: research

Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation
CONCLUSIONS: In AF patients with severe AIS, early OAC use before the guideline-recommended days appeared to increase the risk of bleeding events, although the OAC initiation time seemed not to affect the risk of serious vascular events. The optimal severity-specific timing for OAC initiation after AIS requires further evaluation.PMID:34649296 | DOI:10.1055/a-1669-4987
Source: Thrombosis and Haemostasis - October 14, 2021 Category: Hematology Authors: Po-Yin Chang Weiting Wang Wei-Lun Wu Hui-Chin Chang Chen-Huan Chen Yi-Wen Tsai Shih-Hwa Chiou Gregory Yh Lip Hao-Min Cheng Chern-En Chiang Source Type: research